185 related articles for article (PubMed ID: 1982639)
41. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
[TBL] [Abstract][Full Text] [Related]
42. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.
Bates SE; Shieh CY; Mickley LA; Dichek HL; Gazdar A; Loriaux DL; Fojo AT
J Clin Endocrinol Metab; 1991 Jul; 73(1):18-29. PubMed ID: 1675220
[TBL] [Abstract][Full Text] [Related]
43. [Pharmacological control of P-glycoprotein expression].
Muller C; Bailly JD; Jaffrezou JP; Goubin F; Laurent G
Bull Cancer; 1994 May; 81(5):386-91. PubMed ID: 7749215
[TBL] [Abstract][Full Text] [Related]
44. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
45. Multidrug resistance.
Moscow JA; Cowan KH
J Natl Cancer Inst; 1988 Mar; 80(1):14-20. PubMed ID: 2892943
[TBL] [Abstract][Full Text] [Related]
46. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
47. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Gekeler V; Beck J; Noller A; Wilisch A; Frese G; Neumann M; Handgretinger R; Ehninger G; Probst H; Niethammer D
Ann Hematol; 1994; 69 Suppl 1():S19-24. PubMed ID: 7914748
[TBL] [Abstract][Full Text] [Related]
48. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Qian XD; Beck WT
Cancer Res; 1990 Feb; 50(4):1132-7. PubMed ID: 1967551
[TBL] [Abstract][Full Text] [Related]
49. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
50. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
51. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
52. Chemoresistance in breast tumors.
Giai M; Biglia N; Sismondi P
Eur J Gynaecol Oncol; 1991; 12(5):359-73. PubMed ID: 1680689
[TBL] [Abstract][Full Text] [Related]
53. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
54. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Theyer G; Schirmböck M; Thalhammer T; Sherwood ER; Baumgartner G; Hamilton G
J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
[TBL] [Abstract][Full Text] [Related]
55. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance.
Yu DS; Ma CP; Chang SY
Urol Res; 2000 Apr; 28(2):86-92. PubMed ID: 10850629
[TBL] [Abstract][Full Text] [Related]
56. Genetic aspects of multidrug resistance.
Biedler JL
Cancer; 1992 Sep; 70(6 Suppl):1799-809. PubMed ID: 1355404
[TBL] [Abstract][Full Text] [Related]
57. Transcriptional regulation of multidrug resistance in breast cancer.
Glazer RI; Rohlff C
Breast Cancer Res Treat; 1994; 31(2-3):263-71. PubMed ID: 7881104
[TBL] [Abstract][Full Text] [Related]
58. Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance.
Hait WN; Aftab DT
Biochem Pharmacol; 1992 Jan; 43(1):103-7. PubMed ID: 1346493
[TBL] [Abstract][Full Text] [Related]
59. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
60. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.
Herzog CE; Tsokos M; Bates SE; Fojo AT
J Biol Chem; 1993 Feb; 268(4):2946-52. PubMed ID: 8094079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
